Next-generation dendritic cell and exosome vaccines in NSCLC: integrating personalized medicine, nanotechnology, AI, and microfluidics for enhanced immunotherapy.

Abstract

Lung cancer remains the leading cause of cancer-related mortality, and non-small cell lung cancer (NSCLC) accounts for most cases. Despite advances in immune checkpoint inhibition, many patients do not respond, prompting interest in Dendritic Cell (DC) vaccines and DC-derived Exosome (DEX) platforms as personalized immunotherapeutic strategies. This narrative review examines the current clinical status of DC and DEX vaccines in NSCLC. It distinguishes therapeutic DEX products from tumor-derived extracellular vesicles, circulating diagnostic biomarkers, and exosome-mimetic nanoparticles, which differ in source, function, production, and regulation. PubMed, Google Scholar, and ClinicalTrials.gov were searched from 2000 to 2026; no formal risk-of-bias assessment or dual screening was performed, and selection bias cannot be excluded. No head-to-head clinical comparison of DCVs and DEX vaccines exists in NSCLC, and neither is supported by phase III data. We assess four enabling technologies, microfluidics, AI, nanoparticle engineering, and personalized medicine, and identify unresolved obstacles, including absent validated predictive biomarkers, lack of DEX-specific Good Manufacturing Practice (GMP) and potency standards, inter-batch variability, regulatory ambiguity, high costs, and biological heterogeneity, before proposing an explicitly hypothetical closed-loop approach. Clinical translation requires standardized methodology, validated biomarkers, GMP-compliant production, prospective trials in earlier-stage disease, and direct comparison of DCV and DEX platforms. Non-Small Cell Lung Cancer (NSCLC) is the most prevalent kind of lung cancer, which continues to be the primary cause of cancer-related deaths globally. Many patients do not respond to immunotherapies, even though others do. Dendritic Cells (DCs), specialized immune cells that help the body identify and fight cancer, are a viable platform for developing customized vaccines. However, they have drawbacks, including high cost and complex production. An alternative strategy uses exosomes, microscopic particles DCs release that carry crucial immune signals. Exosomes can activate the immune system in several ways and are safer than whole cells, though more research is needed to confirm their effectiveness. Artificial intelligence can help create customized vaccines based on each patient’s tumor; nanoparticles can deliver vaccines more precisely to target cells; microfluidic devices can quickly separate and engineer exosomes; and nanotheranostics may enable real-time monitoring of treatment responses. Although encouraging, most of these methods are still in their infancy and have been tested only in cells or animals, not in humans. We conclude that these vaccines are not yet ready for widespread use and that the next step is carefully planned clinical trials with specific objectives. We should not make more promises than the facts warrant.

Abstract as supplied by the indexing source. © the authors / publisher.